

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application:

1. (Currently Amended) A peptide comprising at least one epitope recognized by a BAT monoclonal antibody, selected from:
 - (a) a peptide having the sequence of any one of SEQ ID NOs ~~[[1]]~~ 11 through ~~[[17]]~~ 16; ~~or~~
 - (b) a homolog having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; and
 - (e) a combination of peptides according to (a), (b), (c) or (d).
2. (Currently Amended) The peptide according to claim 1, wherein the peptide is selected from:
 - (a) a peptide having the sequence of any one of SEQ ID NOs ~~1, 6, 8, 9, 10, 14~~ ~~[[,]]~~ or 16; ~~or~~
 - (b) a homolog having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; ~~or~~ and
 - (e) a combination of peptides according to (a), (b), (c) or (d) which retains the biological activity thereof.
3. (Currently Amended) A peptide according to claim 1 capable of inhibiting binding of BAT monoclonal antibody to lymphoma cells.
4. (Original) The peptide according to claim 3, wherein the lymphoma cells are Daudi or Jurkat cells.
5. (Currently Amended) The peptide according to claim 3, selected from:

- (a) a peptide having the sequence of any one of SEQ ID NOs ~~[[1]]~~ 11 through ~~[[17]]~~ 16; ~~or~~
 - (b) a homolog having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; ~~or~~ and
 - (e) a combination of peptides according to (a), (b), (c) or (d) which retains the biological activity thereof.
6. (Currently Amended) The peptide according to claim 3, selected from:
- (a) a peptide having the sequence of any one of SEQ ID NOs ~~1, 6, 8, 9, 10, 14~~ ~~[[,]]~~ or 16; ~~or~~
 - (b) a peptide having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; ~~or~~ and
 - (e) a combination of peptides according to (a), (b), (c) or (d).
7. (Currently Amended) A peptide useful for inhibiting tumor growth selected from:
- (a) a peptide having the sequence of any one of SEQ ID NOs ~~[[1]]~~ 11 through ~~[[17]]~~ 16; ~~or~~
 - (b) a homolog having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; and
 - (e) a combination of peptides according to (a), (b), (c) or (d).
8. (Currently Amended) The peptide according to claim 7, wherein the peptide is selected from:

- (a) a peptide having the sequence of any one of SEQ ID NOs ~~1, 6, 8, 9, 10, 14~~[[,]] or ~~16~~; ~~or~~
 - (b) a homolog having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; ~~or~~ and
 - (e) a combination of peptides according to (a), (b), (c) or (d).
9. (Currently Amended) A peptide capable of inducing an immune response against tumor cells, selected from:
- (a) a peptide having the sequence of any one of SEQ ID NOs [[1]] 11 through [[17]] ~~16~~; ~~or~~
 - (b) a homolog having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; and
 - (e) a combination of peptides according to (a), (b), (c) or (d).
10. (Currently Amended) The peptide according to claim 9, wherein the peptide is selected from:
- (a) a peptide having the sequence of any one of SEQ ID NOs ~~1, 6, 8, 9, 10, 14~~[[,]] or ~~16~~; ~~or~~
 - (b) a homolog having at least 70% identity with a peptide of (a) and retains the biological activity thereof; ~~or~~
 - (c) a fragment of a peptide of (a) or (b) having the biological activity thereof; ~~or~~
 - (d) a variant, derivative or salt of a peptide of (a), (b) or (c) which retains the biological activity thereof; ~~or~~ and
 - (e) a combination of peptides according to (a), (b), (c) or (d).
11. (Withdrawn, Currently Amended) A polynucleotide encoding at least one peptide recognized by a BAT monoclonal antibody, according to claim 1.

12. (Withdrawn, Currently Amended) The polynucleotide according to claim 11, having a sequence selected from SEQ ID NOs ~~[[18]]~~ 26 through ~~[[32]]~~ 31.
13. (Withdrawn, Currently Amended) The polynucleotide according to claim 11, having a sequence selected from SEQ ID NOs ~~18, 22, 24, 25, 29~~~~[[,]]~~ and 31.
14. (Withdrawn, Currently Amended) A construct comprising a polynucleotide according to claim 11 encoding for at least one peptide recognized by a BAT monoclonal antibody.
15. (Withdrawn, Currently Amended) The construct according to claim 14, wherein the polynucleotide comprises a sequence selected from SEQ ID NOs ~~[[18]]~~ 26 through ~~[[32]]~~ 31.
16. (Withdrawn, Currently Amended) The construct according to claim 14, wherein the polynucleotide comprises a sequence selected from SEQ ID NOs ~~18, 22, 24, 25, 29~~~~[[,]]~~ and 31.
17. (Withdrawn, Currently Amended) A vector comprising a polynucleotide according to claim 11 encoding at least one peptide recognized by a BAT monoclonal antibody.
18. (Withdrawn, Currently Amended) The vector according to claim 17, wherein the polynucleotide comprises a sequence selected from SEQ ID NOs ~~[[18]]~~ 26 through ~~[[32]]~~ 31.
19. (Withdrawn, Currently Amended) The vector according to claim 17, wherein the polynucleotide comprises a sequence selected from SEQ ID NOs ~~18, 22, 24, 25, 29~~~~[[,]]~~ and 31.
20. (Withdrawn) The vector according to claim 17, wherein the vector is a plasmid or a virus.
21. (Withdrawn, Currently Amended) A host cell comprising a vector comprising a polynucleotide according to claim 11 encoding at least one peptide recognized by a BAT monoclonal antibody.
22. (Withdrawn, Currently Amended) The host cell according to claim 21, comprising a polynucleotide having a sequence selected from SEQ ID NOs ~~[[18]]~~ 26 through ~~[[32]]~~ 31.
23. (Withdrawn, Currently Amended) The host cell according to claim 21, comprising a polynucleotide having a sequence selected from SEQ ID NOs ~~18, 22, 24, 25, 29~~~~[[,]]~~ and 31.

24. (Withdrawn) The host cell according to claim 21, capable of expressing at least one epitope recognized by BAT monoclonal antibody.
25. (Original) A pharmaceutical composition comprising as an active ingredient at least one peptide according to claim 1 and a pharmaceutically acceptable carrier.
26. (Withdrawn) A pharmaceutical composition comprising as an active ingredient a polynucleotide according to claim 11 and a pharmaceutically acceptable carrier.
27. (Withdrawn) A method for treating cancer in a subject in need thereof comprising the step of administering a therapeutically effective amount of a composition according to claim 25.
28. (Withdrawn) A method for treating cancer in a subject in need thereof comprising the step of administering a therapeutically effective amount of a composition according to claim 26.
29. (Cancelled)
30. (Withdrawn) An immunomodulatory vaccine comprising at least one peptide according to claim 1, wherein the peptide is recognized by a BAT monoclonal antibody and a pharmaceutically acceptable adjuvant.
31. (Cancelled)
32. (Withdrawn) The vaccine according to claim 30, wherein the adjuvant is selected from the group consisting of an aluminum salt and an oil in water emulsion.
33. (Original) A diagnostic agent for detecting cancer comprising a peptide recognized by a BAT monoclonal antibody, according to claim 1.
34. (Withdrawn) An antibody recognizing at least one peptide according to claim 1.
35. (Withdrawn) The antibody according to claim 35, selected from the group of: intact antibody, an antibody fragment selected from: Fv, F(ab'), F(ab')₂ or a single chain antibody.
36. (Withdrawn) The antibody according to claim 35, selected from the group of: monoclonal antibody, polyclonal antibody, recombinant antibody, synthetic antibody fragment.